Fully dissolvable, temporary stent for opening heart artery blockages

September 17, 2013

The Mount Sinai Medical Center is participating in the nationwide ABSORB III clinical trial testing the performance and potential clinical benefits of a fully dissolvable and temporary drug eluting stent to open heart artery blockages. The randomized trial aims to compare the efficiency and safety of Absorb Bioresorbable Vascular Scaffolds (Absorb BVS) in coronary artery disease patients and compare it to the current standard of care—drug eluting metal stents.

Absorb BVS is a flexible artery support tube made of a naturally dissolvable material called polylactide. It is inserted by interventional cardiologists minimally invasively during a . Absorb BVS works to line the interior of a blocked heart artery to keep it open and restore proper blood flow to the heart. The supportive tube then dissolves into the within two years.

"Dissolvable stents may be a future game-changer for the way we treat and heart attack in the United States if proven to show in this nationwide clinical trial," says Samin K. Sharma, MD, Director of Clinical and Interventional Cardiology at The Mount Sinai Medical Center and the Zena and Michael A. Wiener Professor of Medicine at Icahn School of Medicine at Mount Sinai. "The stent is designed to open a blocked heart vessel and eventually dissolve and disappear, leaving no remnants on the heart of a cardiac interventional procedure."

"We look forward to testing this innovative absorbable artery support technology's efficiency and safety at Mount Sinai," says Annapoorna S. Kini, MD, Director of the Cardiac Catheterization Laboratory at The Mount Sinai Medical Center. "Since the stent is designed to completely dissolve into the arterial tissue it may potentially help improve the overall health of a patient's once blocked heart vessel while restoring its natural flexibility and movement."

"Heart disease is still the number one killer of Americans. This is why we need to study in clinical trial every available therapeutic option for our heart patients to improve their overall heart health and prevent future deadly heart attacks," says Roxana Mehran, MD, Director of Interventional Cardiovascular Research and Clinical Trials at Icahn School of Medicine at Mount Sinai. "It is critical that advances in cardiac interventional technology, currently being used on other continents to help unblock arteries, be tested in clinical trial in the U.S."

The randomized ABSORB III clinical trial plans to enroll approximately 2,250 coronary artery disease patients across the country. Mount Sinai hopes to enroll 50 patients.

Recently, Absorb BVS became commercially available in Europe, India, and parts of Latin America and Asia. So far, more than 1,000 patients around the world have been treated with the device. Absorb BVS is made by the global healthcare company Abbott.

Explore further: American first: A patient treated with a disappearing heart device

Related Stories

American first: A patient treated with a disappearing heart device

December 5, 2011
The interventional cardiology team at the Montreal Heart Institute (MHI) used the world's first drug eluting bioresorbable vascular scaffold to successfully treat a woman suffering from coronary artery disease. This landmark ...

Inhalable gene therapy may help pulmonary arterial hypertension patients

July 30, 2013
The deadly condition known as pulmonary arterial hypertension (PAH), which afflicts up to 150,000 Americans each year, may be reversible by using an inhalable gene therapy, report an international team of researchers led ...

Study finds 30 percent lower risk of dying for diabetics with bypass surgery vs. stent

September 12, 2013
People with diabetes have a 30 per cent less chance of dying if they undergo coronary artery bypass surgery rather than opening the artery through angioplasty and inserting a stent, a new study has found.

Mesh-covered stent helps restoration of blood flow in heart attack patients undergoing PCI

October 24, 2012
A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart ...

Cardiac bypass surgery superior to non-surgical procedure for adults with diabetes and heart disease

November 4, 2012
Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.